Dual-Regulated Oncolytic HSV Vectors for Tumor-Specific Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, including immunotherapies, are ineffective for many malignant tumors, particularly those that have relapsed or are refractory, leading to a high unmet need for effective treatment methods that can control disease progression and prolong patient survival.
Innovation Solution
Recombinant herpes simplex virus vectors are developed with transcriptional and translational control mechanisms to enhance tumor-specific replication and immunostimulation, incorporating miRNA target sequences, tumor-specific promoters, and modified glycoproteins to target and lyse tumor cells while minimizing neurotoxicity and off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunotherapies (checkpoint inhibitors, CAR-T) are used to treat malignant tumors, then immune response is stimulated, but treatment effectiveness is limited (single-drug effective rate only about 30%, mainly targets B cell tumors)
Solution Approach 1:
The oncolytic herpes simplex virus vector is engineered to perform multiple functions simultaneously: (1) selective replication and lysis of tumor cells through ICP34.5 gene regulation, (2) stimulation of innate immune response via cGAS-STING pathway activation, (3) presentation of tumor antigens to induce adaptive immune response, and (4) potential combination with checkpoint inhibitors. This multi-functional design addresses the limited versatility of current single-modality immunotherapies.
Solution Approach 2:
The viral vector system segments the anti-tumor immune response into distinct components: (1) direct oncolytic effect from viral replication, (2) innate immune activation through cytosolic DNA sensing, (3) adaptive immune priming through antigen presentation, and (4) immune checkpoint modulation. This segmentation allows each component to be optimized and combined with other therapies targeting different aspects of the immune response.
2Reliability
If oncolytic viruses are used to enhance tumor-specific replication and immune stimulation, then anti-tumor activity is improved, but safety concerns arise (neurotoxicity and off-target effects)
Solution Approach 1:
The virus is engineered with tumor-specific properties through: (1) deletion of ICP34.5 gene to restrict replication to cells with elevated miR-124 (tumor cells), (2) incorporation of tumor-specific promoters to drive transgene expression only in tumor cells, and (3) use of miRNA target sequences to further limit viral gene expression to tumor compartments. This local quality control minimizes off-target effects in healthy tissues including the nervous system.
Solution Approach 2:
The cGAS-STING pathway acts as an intermediary mechanism that converts viral replication in tumor cells into targeted immune activation. The viral DNA in the tumor cell cytoplasm is recognized by cGAS, which activates STING to induce type I interferon production and immune cell recruitment. This intermediary mechanism ensures immune stimulation is localized to tumor sites where viral replication occurs, preventing systemic immune activation and neurotoxicity.
3Reliability
If standard treatment options (surgery, radiotherapy, chemotherapy) are used for advanced tumors, then some tumors can be controlled, but most patients with advanced tumors still have poor prognosis
Solution Approach 1:
The oncolytic virus provides continuous anti-tumor action through: (1) autonomous replication within tumor cells to amplify the therapeutic effect, (2) sustained immune activation through persistent antigen presentation and immune cell recruitment, and (3) potential for repeated dosing to maintain therapeutic pressure. This continuous action addresses the limitation of single-dose or finite-duration standard therapies.
Solution Approach 2:
The viral vector system is designed to be self-amplifying and self-sustaining: (1) the virus replicates autonomously within tumor cells without requiring external administration of additional viral particles, (2) the immune response generated is self-propagating through antigen presentation and immune cell activation, and (3) the system can selectively target and eliminate tumor cells while sparing healthy tissue. This self-service capability reduces the need for intensive external intervention and maintains prolonged therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vectors demonstrate significant anti-tumor activity, enhancing tumor cell killing and immune response, with improved safety and efficacy in preclinical models of various cancer types, including pancreatic, liver, and B-cell lymphoma.
Implementation Method 1
the miRNA target sequences can bind at least two different miRNAs (e.g., one or more of miR-124, miR-124*, and miR-143)
Data Source
AI summary
A herpes virus vector is provided with both transcriptional and translational control. Within various embodiments the herpes virus vector is based upon a modified herpes virus and has both ICP27 and ICP34.5 under control of a CEA promoter and miRNA-124/143, respectively, and deletion of at least one copy of terminal repeat long region is provided to increase safety without sacrificing efficacy. The herpes virus vector can also incorporate a virus-expressed cytokine cassette encoding IL-12, IL-15/IL-15RA under the control of CXCR4 promoter.